Target intelligence / Profile preview

SRY-box transcription factor 18 (SOX18)

Target
SOX18
Molecular classification
Transcription factor, SOXF Transcription Factor Family
01

Overview

SRY-box transcription factor 18 (SOX18) is a member of the SOXF transcription factor family responsible for controlling gene expression by binding to DNA through its highly conserved HMG box domain. SOX18 is crucial for embryonic development of blood and lymphatic vessels and continues to modulate endothelial cell functions in adult tissues. Its activity includes homodimerization and interaction with other transcription factors such as MEF2C and RBPJ. SOX18 is highly conserved among vertebrates and can regulate a broad array of genes through direct DNA binding and dimer formation, distinguishing its transcriptional signature from related factors like SOX7 and SOX17. Aberrant SOX18 expression or activity is implicated in angiogenesis-associated diseases, including various cancers and cardiovascular conditions. Pharmacologic targeting of SOX18—for example, by blocking its dimerization—can disrupt endothelial gene programs, suggesting a promising strategy for both anti-angiogenic and anti-tumor therapies. However, its widespread roles in development and vascular homeostasis present notable safety challenges.

Other names
Transcription factor SOX-18SOX18HLTRSHLTSSRY (sex determining region Y)-box 18SRY-box 18
02

Mechanism of action

Inhibition of SOX18 dimerization or transcriptional activity

03

Biological functions

Vasculogenesis (formation of blood vessels)Angiogenesis (development of new blood vessels)Lymphangiogenesis (formation of lymphatic vessels)Hair follicle developmentEndothelial cell fate regulationTransactivation of gene promoters
04

Disease associations

Cancer (stomach, colorectal, ovarian, liver, endometrial)Cardiovascular disease (e.g., atherosclerosis)Wound healingVascular malformations
05

Safety considerations

Off-target effects on normal vasculogenesis and lymphangiogenesis if SOX18 is inhibitedPotential developmental toxicity (since SOX18 functions in embryonic vascular development)
06

Interacting drugs

Small molecule SOX18 inhibitor

1 more in the full profile.

07

Biomarkers

SOX18 expression levels (as markers for tumor progression, response to therapy, or vascular disease)

Beyond the preview

Go deeper on SRY-box transcription factor 18 (SOX18).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRY-box transcription factor 18 (SOX18).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call